NCT07171047

Brief Summary

This study is investigating whether taking sodium bicarbonate, a common supplement used by endurance athletes, can improve cycling performance during prolonged exercise and in a time trial. Sodium bicarbonate may help reduce muscle acidity, which could delay fatigue and improve performance. The goal of this study is to determine if this supplement can help athletes perform better during long, intense efforts like those seen in real competitions. Participants in this study are well-trained cyclists who will complete two exercise trials in a laboratory setting. Each trial involves three hours of moderate cycling followed by a 20-30-minute time trial at maximum effort. Before each trial, participants will take either sodium bicarbonate or a placebo. The study will measure performance outcomes, such as time trial results, as well as physiological responses, including heart rate, oxygen use, and muscle fatigue. Researchers hope to better understand how sodium bicarbonate can help endurance athletes and provide guidelines for its use in competitive sports.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable healthy

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 12, 2025

Completed
3 days until next milestone

Study Start

First participant enrolled

September 15, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2025

Completed
Last Updated

March 30, 2026

Status Verified

March 1, 2026

Enrollment Period

3 months

First QC Date

July 25, 2025

Last Update Submit

March 27, 2026

Conditions

Keywords

BicarbonateEndurance trainingCyclingTime trial

Outcome Measures

Primary Outcomes (1)

  • Endurance performance

    Difference in time trial performance (average power in watts) between placebo and verum condition

    20-30 minutes, immediately after completion of the time trial for each condition (Placebo and Verum), assessed on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

Secondary Outcomes (16)

  • Difference in questionnaire score - gastrointestinal symptoms

    6.5 hours (rest, breakfast, every 30min during 3-hour low-intensity, after TT) for each condition (Placebo and Verum), on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

  • Difference in questionnaire score - Energy & Confidence

    3 hours (every 30min during 3-hour low-intensity) for each condition (Placebo and Verum), assessed on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

  • Difference in questionnaire score - rate of perceived exertion

    3.5 hours (every 30min during 3-hour low-intensity, after TT) for each condition (Placebo and Verum), assessed on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

  • Difference in blood count

    6.5 hours (rest, every 30min during 3-hour low-intensity, after TT) for each condition (Placebo and Verum), assessed on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

  • Difference in pH & HCO3 kinetics

    6.5 hours (rest, breakfast, every 30min during 3-hour low-intensity, after TT) for each condition (Placebo and Verum), on test day 1 and test day 2 respectively, with a washout period of 3-7 days between appointments (test days).

  • +11 more secondary outcomes

Study Arms (2)

Placebo then Verum

OTHER

Placebo then Verum 3 hour low-intensity ride followed by a 16 km time trial for both conditions. Supplementation of Placebo or Verum before the exercise start.

Dietary Supplement: Placebo then Verum

Verum then Placebo

OTHER

Verum then Placebo 3 hour low-intensity ride followed by a 16 km time trial for both conditions. Supplementation of Placebo or Verum before the exercise start.

Dietary Supplement: Verum then Placebo

Interventions

Placebo then VerumDIETARY_SUPPLEMENT

Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum

Placebo then Verum
Verum then PlaceboDIETARY_SUPPLEMENT

Intake of 0.3 g/kg bodyweight of maltodextrin with hydrogel as placebo and 0.3 g/kg bodyweight of sodium bicarbonate with hydrogel as Verum

Verum then Placebo

Eligibility Criteria

Age16 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • age 16-50 years
  • well-trained cyclists
  • Proof of physical fitness (e.g. sports medical examination required) for measurements with higher intensities (e.g. endurance tests, competition simulation)
  • \>10h endurance training per week

You may not qualify if:

  • Systemic disease or other known pathology in the organs: heart, lungs, kidney, stomach, spleen, liver, gall bladder, and intestines.
  • Evidence of pulmonary disease: forced expiratory volume in one second/forced expiratory volume \< 70% with/without symptoms (cough, sputum) or other evidence of pulmonologic disease.
  • Diabetes II.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Red Bull Athlete Performance Center

Thalgau, Salzburg, 5303, Austria

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Double blinded two-intervention crossover study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Researcher

Study Record Dates

First Submitted

July 25, 2025

First Posted

September 12, 2025

Study Start

September 15, 2025

Primary Completion

December 12, 2025

Study Completion

December 12, 2025

Last Updated

March 30, 2026

Record last verified: 2026-03

Locations